Research Article
The Protection Role Nano-Doped Zinc Oxide on F2-Isoprostane As Biomarkers of Oxidative Stress in STZ Induced Diabetic Retinopathy in Male Rats
Soheir N Abd El-Rahman*
Corresponding Author: Soheir N Abd El-Rahman, Department of Crops Technology Research, Food Technology Research Institute, Agricultural Research Center, Giza, Egypt
Received: September 10th, 2020; Revised: September 16th, 2020; Accepted: September 16th, 2020 Available Online: January 11, 2021
Citation: Soheir N Abd El-Rahman, Department of Crops Technology Research, Food Technology Research Institute, Agricultural Research Center, Giza, Egypt
Copyrights: ©2020El-Rahman SNA.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share :
  • 281

    Views & Citations
Oxidative stress (OS) has been suggested as one of basic mechanism behind the development of type 2 diabetes especially diabetic retinopathy (DR). Isoprostanes (IsoPs) are involved in type 2 diabetes and increased in pathological conditions associated with OS. Our present study was designed to prepare Cl: ZnOnanoparticales (Cl: ZnONPs) and evaluate the effect of ZnCl2 and Cl: ZnONPs at (5 mol 10 mg/kg bw) on retinal oxidative stress in STZ-induced diabetic rats. The male albino rats treated with one dose of streptozotocin (60 mg/kg bw). The diabetic rats adminst rated Zn Cl2 and Cl: ZnONP (5 and 10 mg/kg bw) orally for 3 days. The results investigated that TEM of Cl: ZnONPs has average particle size 14.5-70 nm. Serum insiulin and SOD were decreased and serum glucose and IsoPs were increased significantly (P≤0.05) 72h after treatment with STZ (60 mg/kg bw) than other groups. Asignificant decreased (P≤ 0.05) in glucose and F2-IsoPs levels and significant increase in insulin and SOD levels have been detected also in retinal in STZ diabetic rats which treated with ZnCl2 and Cl: ZnONPs (5 and 10 mg/kg bw). Cl: ZnONPs (10 mg/kg bw) + (60 mg/kg bw) gave the best results compared to ZnCl2 (5 and 10 mg/kg bw) + STZ and Cl: ZnONPs (5 mg/kg bw) + STZ. In conclusion, Cl: ZnONPs have a highly protective effect against hyperglycemia and diabetic retinopathy oxidative stress, especially at (10 mg/kg bw).
Keywords: Diabetic retinopathy, Streptozotocin, Cl: ZnOnanoparticales, Isoprostanes (Isops), Oxidative stress

Diabetes mellitus is a group of metabolic diseases in which has high blood sugar in person, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produce [1]. All over the world there are a large number of people suffer from diabetes [2], approximately (25.9%) [3].

Oxidative stress (OS) due to the imbalance between pro-oxidant/antioxidant status results in generation of reactive oxygen species (ROS) and free radicals or impairedantioxidant defense system [4], subsequent modification of biomolecules such as protein, lipids and nucleicacids.Excessive generation of ROS and free radicals have been implicated in a variety of pathological events such as ischemia-reperfusion injury, cardiovascular disease [5] hepatorenal syndrome [6], scleroderma [7], smoking [8], coronary reperfusion injury [9], atherosclerosis [10], diabetes mellitus [11,12] and neurodegenerative disease [5]. Oxidative stress appears to be an integral and possibly causative part of the pathogenesis of diabetic retinopathy. Compelling evidence has been provided that both insulin-dependent and non–insulin-dependent diabetic patients are under conditions of oxidative stress and thatthe complications of diabetes mellitus (thereafter indicated as diabetes) could be partially mediated by oxidative stress [13], and that peroxide formation is increased in elevated glucose solutions [14,15]. Oxidative damage of cellular membranes has been suggested as a common mechanism in a large number of bio pathological conditions. It can be measured by either primary or secondary end products of peroxidation [16]. While secondary end products include thiobarbituric reactive substances (TBARS), F2-like products termed F2-isoprostanes (F2-IsoPs) [17,18]. Increased levels of F2-IsoPs can be found in the plasma of patients affected with type I and type II diabetes [11,19] and in animal models of diabetes [20], and currently are used as which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
in vivo indicators of lipid peroxidation [13,11,21,22].Zinc (Zn) is the most abundant trace intracellular element required for a number of cellular processes, including cell proliferation, reproduction, immune function and defense against free radicals [23]. It plays an important role as an antioxidant, protects cellular components from oxidation, [24]an activator for more than three hundred enzymes in the body [25], and in different metabolic pathways including glucose metabolism [26].Also, Zinc promotes hepatic glycogens through its actions on the insulin pathways, storage, and secretion [27] and thus improves glucose utilization [28]. Due to its fast electron transfer capability, ZnO is a key material for fabrication of bio membranes, and enzymatic detective devices [29]. Many studies have addressed the importance of ZnO as an antioxidant and a therapeutic agent in several free radicals initiating systems [26,30]. Nano-ZnO is a product whose particle diameter is between 1to 100 nm. More recently, the study of ZnO nanoparticles is a very active area [31,32]. Umrani and Paknikar[33] reported that the antidiabetic effects of ZnONPs through induction of insulin, also, Umrani and Paknikar [23] proved the ability of ZnONPs for controlling of blood glucose in diabetic rats. Soheir et al. [34]investigate the useful effects of high dose of F: ZnO and Cl: ZnO nanoparticles in protection diabetic rats against hyperglycemia and retina against oxidative stress. There is only one study thatmonitored the effect of Cl: ZnO nanoparticles on diabetic rats, but there is not previous study carried out with Cl: ZnO nanoparticles on the role of isoprostane during diabetic rats. Therefore, this work designed to prepare ZnO nanoparticles doped with chlorine (Cl: ZnOPNs) and reviews the role of ZnCl2andCl: ZnONPs on F2-Isoprostane as biomarkers of oxidative stress in retinal in relation to type II diabetes in rats.



The ZnO nanoparticles doped with chlorine was prepared by a chemical solution method from zinc acetate (ZnAc) and oxalic acid. The preparation is as follows: 20 mL of a 0.5 M ethanolic solution of oxalic acid was added drop-by-drop to 20 mL of a 0.1 M ethanolic solution of ZnAc under stirring and maintained at 60°C for 3 h. Then 0.5 M of aqueous solution of ammonium chloride (NH3Cl) was added to the abovesolution in order to get at5% Cl/Zn ratio. A white precipitate was obtained, which was separated by filtration and washed with a mixture of 75:25(water: Ethanol). This precipitatewas dried in an oven at a temperature of100°C for 24 h. The obtained precursor was finally calcined at500°C for 2 h, with a heating rate of 5°C/min. All the reagents used in the experiments were of analytical grade and used directly as purchased.
The structure was analyzed by FTIR spectra (FTIRNicolet6700).Surface Morphology was analyzed by SEM (Quanta 3D FEG/ FEI) and TEM (JEOL, Tokyo, Japan) operating at 60 kV.

Biological methods

Male albino adult rats (60 animals weighing 130g ± 5) were obtained from the private market, Helwan, Giza, Egypt, then transported to Animal House of Ophthalmology Research Institute, Giza, Egypt. Rats were housed in individual cages with screen bottoms and fed on basal diet (corn starch 70%, casein 10%, corn seed oil 10%, cellulose 5%, salt mixture 4% and vitamins mixture 1%) for ten days. After equilibration, rats were weighted and divided into six groups (ten animals per each) everyone was assigned to one of the six diet groups (G1: Negative Control (NC), G2: STZ-treated group that injected with a single ip dose of STZ (60 mg/kg b.w), G3: Treated group that received a single dose of STZ(60 mg/kg b.w)+ single daily oral low dose of ZnCl2(5 mg/kg b.w),G4: Treated group that received a single dose of STZ(60mg/kg b.w) + single daily low dose of Cl: ZnONPs (5mg/kg b.w), G5: treated group that received a single dose of STZ(60 mg/kg b.w) + single daily oral high dose of ZnCl2 (10 mg/kg b.w), G6: Treated group that received a single dose of STZ(60mg/kg b.w) + single daily high dose of Cl: ZnONPs (10mg/kg bw).Rats were sacrificed at 0, 24, 48 and 72 h after STZ treatment. Before the rats were sacrificed, blood was collected from the orbital sinus and serum was prepared and kept frozen at -20°C until the time of assay. Each eye was immediately enucleated, the lens was removed, and the retina was gently peeled away from the pigment epithelium and placed in 500 ı`l ice-chilled 10 mmol/l sodium phosphate buffer, pH 8.0.

Measurements of blood glucose and insulin

Blood glucose (mg/dL) was estimated by glucose oxidase method using the kit supplied by SPINREACT (SantEstevadeBas, Girona, Spain) according toSoheir, Reda andSheikh [35], we measured blood glucose in all experimental animals before the beginning of the experimental procedures, after streptozotocin injection. After that, blood glucose was monitored in all experimental animals, and results were obtained at 0, 24, 48 and 72hof the experimental period. Serum insulin was measured using an insulin radio immunoassay kit.


The enzymatic activity of retinal SOD was measured as described by Ohkuma et al. [36] Retinal.F2-IsoPs were measured using a com­petitive enzyme-linked immunoassay (ELISA) kit according to instructions (Cayman Chemical, Ann Arbor, MI) [37].
Statistical analysis

The results are represented as mean ±SE and statistically analyzed by using one-way ANOVA. Accepted level of significance (P ≤ 0.05).


IR Spectra

Figure 1shows the FT-IR at sorption spectrum prepared sample (Cl: ZnONPs). The peak at 470  is the characteristic distinct stretching vibration of zinc oxide. The broad absorption peak at 3400  can battributed to the characteristic absorption of hydroxyls group. These results agree with Soheir et al. [35]. They reported that the undoped ZnO, anabsorotion peak is observed centered at 372nm (3.33 eV), which is in good agreement with previously reported works of ZnO single crystals and Cl: ZnONPs.

Scanning electron microscopy (SEM)

Figure 2shows the SEM images of the Cl: ZnONPs powder prepared with chlorine doping. Cl: ZnONPs shows a rode shape. The results of this study agree with Soheir et al. [35], and they reported that the ZnO nano powders prepared with fluorine and chlorine and doping have average particle size 17.7 and 59.3 nm, respectively.

Transmission electron microscoupe (TEM)        
Figure 3 shows the Cl: ZnONPs powder prepared with chlorine doping have average particle size 14.5-70.0nm.

Biochemical markers

Table 1shows the changes of serum glucose levels induced by ZnCl2 and Cl: ZnONPs in diabetic rats. Experimental groups treated byZnCl2 and Cl: ZnONPs (5 and 10 mg/kg bw) for 3 days, showed a significant (P≤0.05) decreased in serum glucose levels, it found to be (138.022, 116.094 mg/dl), (117.962, 102.964 mg/dl) at 5 and 10mg/kg bw), respectivelyafter72h. Additionally, Cl: ZnONPs (10mg/kg bw)+STZ (60 mg/kg bw) treated group resultswere close to normal values thatshowed inNC group. This showed a great anti-diabetic activity of zinc oxide nanoparticles, as zinc has been elucidated to be a potent metal that improves glucose utilization and metabolism through its potent influence on enhancement of hepatic glycogenesis through actions on the insulin signaling pathway [35]. Alkaladi et al. [38] showed a great reduction in blood glucose level in diabetic groups treated with ZnONPs, SNPs and insulin. However, ZnONPs induce more reduction than SNP. Rehal et al. [31] reported that at 30, 60, 90 and 120 min, the plasma glucose levels in the STZ-induced rats. That was treated with Vildagliptin, ZnONPs, and various combinations of the two, groups, for 7 weeks showed significant improvements compared to the diabetic group (group II). The maximum improvement in the reduced plasma glucose levels was observed in the rats treated with the combination therapy (Vildagliptin plus 10 mg/kg/d ZnONPs, group IIIh) compared to diabetic group and the other treated groups [39]. Also, a great reduction in blood glucose level in diabetic groups treated with low and high dose of F: ZnONPs and Cl: ZnONPs, it found to be 119.03, 117.10, 108.97 and 103.97 mg/dl after 72 h, respectively [35].

Our results revealed thatZnCl2 and Cl: ZnONPs(5 and 10 mg/kg bw) +STZ (60 mg/kg bw)were significantly (P≤0.05) increased serum insulin level (290.40,328.40 uIV/ml),(310.40,369.80 uIU/ml) at (5 and 10mg/kg bw), respectively, compared to (PC)(177.40 uIU/ml) (Table 2).The serum insulin levels were significantly decreased in the diabetic group compared to the control group[39]. This result may be due tozinc could enhance the glucose stimulated insulin secretion from rat isolated pancreatic islets [40].Umrani and Paknikar [34]demonstrated that ZnONPs did not possess the risk of hypoglycemia in living organisms so it can act as an insulin secretor/due to accumulation of zinc in the secretory vesicle of B cells using transporter 8 [41]. Zinc transporters are also identified in adipose tissues and liver [35,42]. Treatment with ZnONPs. Induced a significant increase in the serum insulin levels compared to the diabetic group (NC)[39]. The groups administration high dose of F: ZnONPs and Cl: ZnONPs gave best results (326.40 and 367.80 pg/ml), respectively, compared to PC (175.40 pg/ml). ZnONPs and SNP could increase serum insulin level in diabetic groups, it was found (79.4% and 3%), respectively if compared with diabetic groups treated with insulin (97.3%). It appeared that ZnONPs also induced more insulin secretion if compared to the effect of SNPs [31]. ZON treatment showed a trend towards a dose-dependent increase in nonfasted serum insulin levels (35% increase at 10 mg/kg dose). However, no significant effects were seen on fasted serum insulin levels after ZON treatment, indicating no risk of hypoglycemia[34].The best results were observed in diabetic rats treated with ZnONPs in a dose of 10mg/kg b.w [43].

Isoprostanes in contrast to lipid hydroperoxides are chemically stable end products of lipid peroxidation, and the measurement of their levels in plasma or urine may permit a sensitive and specific method for detection of lipid oxidative damage in vivo [22]. In the present study the retinal F2-IsoPs levels were significantly (P≤0.05) increased in the diabetic group (0.7162 pg/ml bw) compared to the NC (0.2762pg/ml bw) after 72h (Table 3). Treatment withZnCl2 and Cl: ZnONPs (5 and 10 mg/kg bw) +STZ (60 mg/kg bw) induced a significanty decreased of F2-IsoPs the retina levels 

compared to (PC). The results of Cl: ZnONPs (10 mg/kg bw) +STZ (60 mg/kg bw) was close to normal value that showed in NC group (Table 3).Increase in plasma level of total F2-IsoPs in type 2 diabetic nephropatic patients (P ≤0.01) with respect to controls [44]. Increased F2-IsoPs synthesis during diabetes appears to be responsible in part for the increase in renal TGF-β, α well-known mediator of diabetic nephropathy[6]. Plasma F2-IsoPs levels in STZ-induced diabetic rats were significantly higher than in nondiabetic animals [45].
ZnCl2 and Cl: ZnONPs (5 and 10 mg/kg bw) +STZ (60 mg/kg bw) treatment to STZ-induced diabetic rats are shown in Table 4. The results show significantly (P≤0.05) increased in retina SOD activity (16.29, 21.95 U/ml), (17.15, 24.12 U/ml) after treatment with (5 and 10 mg/kg bw), respectively for 72hthan PC group (11.31 U/ml). ZON treatment increased serum SOD and catalase activity, suggesting antioxidant effects [34].


Based on our results, we can conclude that ZnCl2 and Cl: ZnONPs lead to activation of insulin mechanism of action and induction its synthesis. Cl: ZnONPs + STZ increased SOD and decreased F2-IsoPs activates significantly (P ≤ 0.05). Furthermore, the results elucidated the beneficialeffects of 
high dose of Cl: ZNONPs gave the best results protection retinal against oxidative stress and controlling hyperglycemia.


The author is grateful for the assistance of the Field Crop Technology Research Department, Food Technology Research Institute, Agricultural Research Center, Giza, Egypt. We gratefully acknowledge the assistance of the animal house of Ophthalmology Research Institute, Giza, Egypt. 

  1. Lin Y, Sun Z (2010) Current views on type 2 diabetes. J Endocrinol 204: 1-11.
  2. Yeğin S, Mert N (2013) Investigation on the HbA1c, MDA, GSH-Px and SOD Levels in Experimentally Diabetic Rats. 24: 51-54.
  3. Pfeiffe A, Schatz H (1995) Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 103: 7-14.
  4. Kowluru RA, Kennedy A (2001) Therapeutic potential of antioxidants and diabetic retinopathy. Expert OpinInvestig Drugs 10: 1665-1676.
  5. Halliwell B, Gutteridg JMC (2005) Free radicals in Biology and Medicine, 3rd ed., Clarendon Press, Oxford nukleonika. 3: 67-76.
  6. Morrow JD, Moore KP, Awad JA, Ravenscraft MP, Marini G, et al. (1993) Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome. J Lipid Mediat 6: 417-420.
  7. Stein CM, Tanner SB, Awad JW, Robert J, Morrow J (1996) Evidence of free radical-mediated injury isoprostane overproduction in scleroderma. Arthritis Rheumm 39: 1146-1150.
  8. Morrow JA, Frei B, Longmire AW, Gaziano J, Lynch S, et al. (1995) Increase in circulating products of lipid peroxidation F2-isoprostanes in smokers: Smoking as a cause of oxidative damage. N Engl J Med 332: 1198-1203.
  9. Delanty N, Reilly MP, Pratico D, Lawson JA, McCarthy JF, et al. (1997) 8-epi PGF2 alpha generation during coronary reperfusion: A potential quantitative marker of oxidant stress in vivo. Circulation 95: 2492-2499.
  10. Patrono C, Fiztgerald G (1997) Isoprostanes: Potential markers of oxidant stress in ather. othrombatic disease. ArteriosclerThrombVascBiol 17: 2309-2315.
  11. Dav`IG, Ciabattoni G, Consoli A, Mezzetti A, Falco A, et al. (1999) In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229.
  12. Laight D, Kengatharan KM, Gopaul NK, Anggard EE, Carrier MJ (1998) Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol 125: 895-901.
  13. Davı G, Falco A, Patrono C (2005) Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 7: 256-268.
  14. Hun JV, Smith CC, Wolf SP (1990) Autoxidative glycosilation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424.
  15. Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama, E, et al. (1995) Taurine ameliorates chronic streptozotocin-induced diabetic nephropathy in rats. Am J Physiol l269: F429-F438.
  16. Subramanian K, Sekaran M, Rajes Q, Ikram S (2009) F2-Isoprostanes as Novel Biomarkers for Type2 Diabetes: A review. J Clin BiochemNutr 45: 1-8.
  17. Halliwell B, Grootveld M (1978) The measurement of free radical reactions in humans: Some thoughts for future experimentation. FEBS Letters 213: 9-14.
  18. Morrow J, Harris T, Roberts LJ (1990) Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal Biochem 184:1-10.
  19. Gopaul N, Angaard E, Malle A, Betteridg D, Wolf SP, et al. (1995) Plasma 8-epi-PGF2a levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 368: 225-229.
  20. Tada H, Ishii H, Isoga S (1997) Protective effect of d-alpha-tocopherol on the function of human mesangial cells exposed to high glucose concentrations. Metabolism 46: 779-784.
  21. Roberts L, Morrow J (2000) Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free RadicBiol Med 28:505-513.
  22. Basu S (2004) Isoprostanes: Novel bioactive products of lipid peroxidation. Free Radic Res 38:105-122.
  23. Powell SR (2000) The antioxidant properties of zinc. J Nutr 130(5): 1447S-1454S.
  24. Bruno R, Song Y, Leonard S, Mustacich D, Taylor A, et al. (2007) Dietary zinc restriction in rats alters antioxidant status and increases plasma F2-isoprostanes. J NutrBiochem 18(8): 509-518.
  25. Haase H, Overbeck S, Rink L (2008) Zinc supplementation for the treatment or prevention of disease: current status and future perspectives. Exp Gerontol 43(5): 394-408.
  26. Hanna PM, Kaiiska MB, Jordan SJ, Mason RP (1993) Role of metallothionine in zinc (II) and Chromium (III) mediated tolerance to carbon tetrachloride hepatotoxicity: Evidence against a trichloromethyl radical-scavenging mechanism. Chem Res Toxicol 6: 711-717.
  27. Chausme A (1998) Zinc, insulin and diabetes. J Am Coll Nutr 17(2): 109-115.
  28. Jansen J, Karge W, Rink L (2009) Zinc and diabetes-clinical links and molecular mechanisms. J NutrBiochem 20(6): 399-417.
  29. Zhu X, Yuri I, Gan X, Suzuki I, Li G (2007) Electrochemical study of the effect of nano-zinc oxide on microperoxidase and its application to more sensitive hydrogen peroxide biosensor preparation. BiosensBioelectron 22: 1600-1604.
  30. Alkaladi A, Abdelazim AM, Afifi M (2014) Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats. Int J Mol Sci 15: 2015-2023.
  31. Zhe W, Guangshun W (2004) APD: The Antimicrobial Peptide Database. Nucl Acids Res 32: D590-D592.
  32. Yang Z, Liu Q (2008) Mutation-selection models of codon substitution and their use to estimate selective strengths on codon usage. Mol BiolEvol 25: 568-579.
  33. Umrani RD, Paknika KM (2014) Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Type 1 and 2 diabetic rats. Nanomedicine (Lond) 9: 89-104.
  34. Soheir N, Reda S, Sheikh M (2016) Synthesis and Characterization of Nano-doped Zinc Oxide and its Application as Protective Oxidative Changes in the Retina of Diabetic Rats. J Diabetes Metab 7: 1000691.
  35. Tietz N (1995) Clinical guide to laboratory tests. 3rd ed. Philadelphia. WB Saunders 268-273.
  36. Ohkuma N, Matsuo S, Tutsui M, Ohkawara A (1982) Superoxide dismutase in the epidermis Q4 (author’s transl). Nippon Hifuka Gakkai Zasshi 92: 583-590.
  37. Morrow J, Roberts J (1997) The Isoprostanes: Unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1-21.
  38. El-Gharbawy RM, Emara AM, Risha SEA (2016) Zinc oxide nanoparticles and a standard antidiabetic drug restore the function and structure of beta cells in Type-2 diabetes. Biomed Pharmacother 84: 210-820.
  39. Quesada I, Tuduri E, Ripoll C, Nadel A (2008) Physiology of the pancreatic alpha-cell and glucagon secretion: Role in glucose homeostasis and diabetes. J Endocrinol 199: 5-19.
  40. Williams CR, Contreras JL, Berecek KH, Schwiebert EM (2008) Extracelluler ATP and zinc are co secreted with insulin and activate multiple P2X purinergic receptor channels expressed by islet beta cells topotentiate insulin secretion. Purinergic Signal 4: 393-405.
  41. Rungby J (2010) Zinc transporters and diabetes. Diabetologia 53: 1549-1551.
  42. Husssein SA, EL-Senosil YA, El-Dawy K, Hind A (2014) Evaluation of zinc oxide nanoparticles for insulin, insulin receptors and insulin receptors substrates gene expression in streptozotocoin-induced diabetic rats. Benha Vet Med J 27: 166-174.
  43. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, et al. (2007) Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaper 12(4): 299-306.
  44. Montero A, Munger KA, Khan RZ, Guasch A, Ziyadeh FN, et al. (2000) F2-isoprostant mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 58: 1963-1972.